Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE). - Qian K; Chen QR; He M; Wang ZT; Liu Y; Liang HG; Su ZY; Cui YS; Liu LJ; Zhang Y (Investigational new drugs, 2023)